TACC3 and neoplasm: In this study, FGFR3–TACC3 fusion patients were treated with small molecule multi-target TKI, which inhibited VEGFR, PDGFR, FGFR and c-Kit targets, showing anti-tumor angiogenesis and tumor growth inhibition.